List of Awardees

• Date: October 7–9, 2026
• Location: Pacifico Yokohama, Japan
• Event Link: https://jcd-expo.jp/en/

• Date: October 4–7, 2026
• Location: COEX Convention & Exhibition Center, Seoul, South Korea
• Booth: #300
• Event Link: https://www.mdscongress.org/

We look forward to seeing you in Seoul.

Top-line clinical data from the trial are expected in the first quarter of 2027. In parallel, Dasher Neuroscience is actively pursuing global out-licensing partnerships while concurrently planning a global multi-center Phase 3 trial to accelerate YA-101 toward clinical commercialization as a potential first-in-class therapy for MSA.

“Completing patient enrollment in this global Phase 2 trial represents a major milestone in advancing our lead candidate, YA-101, toward commercialization,” said Dr. Jane Tseng, Chief Executive Officer of Dasher Neuroscience. “This study will provide critical data on both the safety and clinical efficacy of YA-101, laying a solid foundation for licensing discussions with potential global partners as we work to bring this innovative therapy to rare disease patients facing significant unmet medical needs.”

90 Patients Enrolled Across U.S., Japan, and Taiwan Sites

The Phase 2 trial of YA-101 is a global, multi-center, double-blind, placebo-controlled, dose-escalation study. A total of 90 participants have been enrolled across clinical sites in the United States, Japan, and Taiwan.

The trial aims to evaluate the safety, tolerability, pharmacokinetics, and efficacy of YA-101 in patients aged 30 and older diagnosed with MSA according to Movement Disorder Society (MDS) clinical criteria, encompassing both the Parkinsonian subtype (MSA-P) and cerebellar subtype (MSA-C).

The primary endpoint of the trial is the incidence and severity of Adverse Events (AEs) to assess the safety and tolerability profile of YA-101. Secondary endpoints include pharmacokinetic (PK) parameters, as well as clinical efficacy evaluated via the Unified Multiple System Atrophy Rating Scale (UMSARS) and the 10-Meter Walk Test.

U.S. FDA Fast Track and Global Orphan Drug Designations

YA-101 is a New Chemical Entity (NCE) and a D-amino acid oxidase inhibitor (DAOI) that can inhibit inflammatory cytokines, primarily by reducing neuroinflammation and enhancing neuroplasticity to improve disease outcomes. It is being developed with the potential to serve as a novel treatment option for MSA patients worldwide.

YA-101 has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), alongside Orphan Drug Designation (ODD) from regulatory agencies in the U.S., Japan, and the European Union.

MSA is a rare, rapidly progressive, and fatal neurodegenerative disease. Onset typically occurs in a patient’s 50s, with up to 80% of patients becoming severely disabled within 5 years of diagnosis and a mean survival of just 6 to 10 years. Current clinical management is limited to symptomatic relief, with no approved disease-modifying therapies available—representing a critical unmet medical need worldwide.

The global prevalence of MSA is approximately 5 cases per 100,000 individuals, affecting an estimated 15,000 to 50,000 individuals in the U.S., 18,000 to 70,000 in the EU, 12,000 in Japan, and 2,000 in Taiwan. Upon regulatory approval, YA-101 aims to fill this severe treatment gap and offer new therapeutic hope to patients worldwide.

About Dasher Neuroscience Holdings Inc.

Dasher Neuroscience-KY (TPEx: 7829) was listed on the Taiwan Emerging Stock Board on June 3, 2025. It is a biopharmaceutical company focused on using AI to accelerate CNS therapies.

The company’s flagship drug, YA-101, initially targets MSA and is currently in Phase II clinical trials. It has received U.S. FDA Fast Track Designation and ODD in the U.S., Japan, and the EU. Additionally, YA-102 for the treatment of Parkinson’s disease is under development, along with two preclinical pipeline candidates: YA-201 for Alzheimer’s disease and YA-301 for schizophrenia. Upholding its mission to solve unmet medical needs, the company focuses on providing innovative, safe, and effective therapeutic choices. For more information, please visit the company website: www.dasherneuroscience.com.

Rare Disease MSA Phase II Clinical Trial Progresses Smoothly, Launching International Licensing

YA-101 has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) and Orphan Drug Designation (ODD) in the U.S., Japan, and the European Union (EU). These designations not only accelerate the FDA review and approval process but also grant 7 years of market exclusivity in the U.S. In Japan, the designation offers incentives, including extending the re-examination period to up to 10 years, securing its market exclusivity upon future commercialization. Notably, while the EU maintains very strict reviews for orphan drug status, once successfully launched as a breakthrough orphan drug, it will be granted up to 11 years of market exclusivity in the EU.

YA-101 is a New Chemical Entity (NCE) and a D-amino acid oxidase inhibitor (DAOI) that can inhibit inflammatory cytokines, primarily by reducing neuroinflammation and enhancing neuroplasticity to improve disease outcomes.

Jane Tseng, CEO of Dasher Neuroscience-KY, stated: “Currently, YA-101 is undergoing Phase II clinical trials for patients with multiple system atrophy, conducted concurrently across multiple clinical trial centers in the U.S., Japan, and Taiwan. At present, overall patient recruitment is progressing smoothly, and we have simultaneously initiated our steps toward international licensing.”

AI Parkinson’s Drug Expected to Launch Clinical Trials Next Year

In addition to the smooth clinical progress of the rare neurodegenerative disease MSA, Dasher-KY’s AI drug has been selected by the International Linked Clinical Trials (iLCT) program into its “Priority List for Parkinson’s Disease Clinical Development.” As the first drug from Taiwan to be selected, it has instantly leaped into the global Parkinson’s disease R&D spotlight, with the potential to receive clinical trial funding from the UK Parkinson’s research charity, Cure Parkinson’s, in the future.

Furthermore, Dasher-KY has signed a Memorandum of Understanding (MOU) with Helse Bergen HF, Haukeland University Hospital in Bergen, Norway. Both parties will engage in deep exchanges to jointly advance the AI drug into the HYDRA Phase III platform trial, which is expected to become Taiwan’s first new drug to enter a leading global platform trial for Parkinson’s disease.

At the same time, the company has also signed an MOU with the Shake It Up Australia Foundation and an agreement in principle with the Movement Disorders Society of Australia and New Zealand Clinical Trials Network (MDSANZ CTN). This is expected to attract international funding and clinical trial resources, accelerating the implementation of innovative therapies worldwide.

Currently, within Dasher-KY’s pipeline, preclinical research is also underway for neuro-related diseases such as Alzheimer’s disease and schizophrenia. Through this exhibition, the company hopes to exchange and form alliances with domestic and foreign licensing partners, medical institutions, and biotech industry peers, fully driving the global clinical development, registration, and commercialization of CNS AI drugs, and working together to allow patients with neurological diseases to access effective innovative therapies as early as possible.

About Dasher Neuroscience Holdings Inc.

Dasher Neuroscience-KY (7829) was listed on the Taiwan Emerging Stock Board on June 3, 2025. It is a biopharmaceutical company focused on using AI to accelerate CNS therapies.

The company’s flagship drug, YA-101, initially targets MSA and is currently in Phase II clinical trials. It has received U.S. FDA Fast Track Designation and ODD in the U.S., Japan, and the EU. Additionally, YA-102 for the treatment of Parkinson’s disease is under development, along with two preclinical pipeline candidates: YA-201 for Alzheimer’s disease and YA-301 for schizophrenia. Upholding its mission to solve unmet medical needs, the company focuses on providing innovative, safe, and effective therapeutic choices. For more information, please visit the company website: www.dasherneuroscience.com.

• Dates: 16 – 19 July 2026
• Location: Taipei Nangang Exhibition Center
• Booth: No. M434
• Event Link: Exhibitor Profile

• Dates: 22 – 25 June 2026
• Location: San Diego Convention Center, San Diego, USA
• Booth Location: No. 2621, Taiwan Pavilion
• Event Link: https://convention.bio.org

Program Details & Links

• Panel (“From Rules to Results – Can Europe Keep Up in the Global Biotech Race?”): https://www.biocap-europe.com/en/program/programme-overview#eventdate–From-Rules-to-Results-%E2%80%93-Can-Europe-Keep-Up-in-the-Global-Biotech-Race%3F–0c3c91db-843a-4fae-9031-774b12c4c291
• SPARK Europe Showcase: https://www.biocap-europe.com/en/program/programme-overview#eventdate–SPARK-Europe-Showcase–668cf11a-4cb4-486a-9e0c-cbfd6f9ade17

Dasher Neuroscience proudly participated in the World Parkinson Congress 2026 in Phoenix, joining the global Parkinson’s disease community for a week of scientific exchange, collaboration, and meaningful dialogue.

At our exhibition booth, we were pleased to engage with researchers, clinicians, advocacy groups, patients, families, and industry partners, and to share our latest progress in neurodegenerative disease research and therapeutic development. We sincerely thank everyone who visited our booth and took the time to exchange ideas and insights with our team.

A key highlight of the week was our hosted Cocktail Social, featuring a distinguished speaker program. We extend our sincere thanks to all speakers for sharing their perspectives and experiences:

Clyde Campbell, Founder of the Shake It Up Australia Foundation

Group photo with the MUFG team